$28.480
+0.262 (+0.92%)終値時点
SGP の同業比較
In the context of the broader market, SGP competes directly with industry leaders such as KURA and VSTM. With a market capitalization of $926.84M, it holds a significant position in the sector. When comparing efficiency, SGP's gross margin of N/A stands against KURA's 98.84% and VSTM's 89.92%. Such benchmarking helps identify whether SpyGlass Pharma, Inc. is trading at a premium or discount relative to its financial performance.
SpyGlass Pharma Inc の財務パフォーマンス
SpyGlass Pharma has shown a year-to-date change of +78.00%, indicating strong market performance. However, it reported a widening net loss of $19.9 million in Q2 2026, which is a concern for its financial health.
Financials
FY2026Q2
YoY:
+136.28%
-21.97M
Operating Profit
FY2026Q2
YoY:
+128.98%
-19.86M
Net Income after Tax
FY2026Q2
YoY:
+118.52%
-0.59
EPS - Diluted
FY2026Q2
-16.77M
Free Cash Flow
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。